收稿日期: 2026-03-02
修回日期: 2026-05-13
录用日期: 2026-05-18
网络出版日期: 2026-06-27
基金资助
国家自然科学基金(82572595);国家自然科学基金国际(地区)合作与交流项目(W2411075);国家重点研发计划(2024YFC2309600)
Fungal resistance surveillance report in East China in 2025
Received date: 2026-03-02
Revised date: 2026-05-13
Accepted date: 2026-05-18
Online published: 2026-06-27
目的:监测2025年中国华东地区临床分离真菌的抗真菌药物敏感性情况,为临床诊断和治疗提供参考。方法:回顾性分析2025年1月至12月华东地区侵袭性真菌感染协作组(Eastern China Invasive Fungi Infection Group, ECIFIG)收集的临床真菌,采用形态学结合质谱检测对菌种进行鉴定,结合内转录间隔区测序和β微管蛋白基因测序技术对结果进行复核。采用微量肉汤稀释法进行抗真菌药物(唑类药物,包括氟康唑、伊曲康唑、伏立康唑、泊沙康唑和艾沙康唑;棘白菌素类药物,包括米卡芬净、阿尼芬净和卡泊芬净;两性霉素B和氟胞嘧啶)的药敏试验。结果:2025年,华东地区共收集酵母菌2 044株,血液为主要标本类型,占37.06%(763/2044);白念珠菌占比38.51%(793/2044),热带念珠菌占比18.89%(389/2044),近平滑念珠菌占比16.61%(342/2044),光滑念珠菌占比15.20%(313/2044),克柔念珠菌占比1.75%(36/2044)。2025年,华东地区共收集丝状真菌310株,主要为曲霉,包括烟曲霉(62.26%)、黄曲霉(26.45%)、黑曲霉(5.81%)和土曲霉(3.55%);丝状真菌主要分离自呼吸道标本,其中痰液标本占比53.23%,肺泡灌洗液标本占比31.29%。念珠菌的耐药性主要表现为对唑类耐药,白念珠菌对氟康唑耐药率为3.66%,泊沙康唑非野生型菌株占比为6.81%。热带念珠菌对氟康唑耐药率为29.05%,对伏立康唑非敏感菌株为24.45%,伊曲康唑非野生型菌株占比为17.48%,泊沙康唑非野生型菌株占比为61.18%;近平滑念珠菌对氟康唑耐药率为11.7%,两性霉素B非野生型菌株占比为2.30%;光滑念珠菌对氟康唑耐药率为5.75%;伊曲康唑、泊沙康唑、伏立康唑非野生型菌株占比分别为1.92%、12.78%、28.12%。烟曲霉对伏立康唑的中介率为3.63%,耐药率为5.18%,艾沙康唑中介率为1.04%,耐药率为4.70%,对伊曲康唑的非野生型比率为3.11%;黄曲霉对卡泊芬净、两性霉素B和唑类药物均为野生型菌株。结论:2025年,中国华东地区真菌监测网共收集酵母菌2 044株,主要分离自血液标本,白念珠菌占比最高;共收集丝状真菌310株,主要分离自呼吸道标本,烟曲霉占比最高。热带念珠菌对唑类药物耐药性明显高于其他念珠菌种;烟曲霉对唑类耐药率为5.18%,较往年有所升高;未发现黄曲霉唑类耐药菌株。
关键词: 中国华东地区; 真菌耐药性监测; 侵袭性真菌感染; 抗真菌药物敏感性试验
林慧萍 , 王东江 , 郭建 , 李腾 , 杨思敏 , 王莎莎 , 周爱萍 , 胡靓 , 田文杰 , 麻浙效 , 吴家棋 , 古丽孜巴·亚力买买提 , 张燕 , 陈会 , 萧晨路 , 郭玮 , 王苏珍 , 万智敏 , 韩春华 , 王盛华 , 温开镇 , 李彬 , 陈燕林 , 谢屿平 , 陈雯静 , 孟红委 , 李志夫 , 徐和平 , 何磊 , 魏慕筠 , 李婷华 , 杨海慧 , 奚卫 , 吴永琴 , 鲁怀伟 , 庄亦晖 , 刘研 , 沈丹丹 , 秦洁 , 李晟超 , 杨青 , 黄晶晶 , 唐朝贵 , 徐杰 , 任建敏 , 刘淑芬 , 胡秀华 , 商安全 , 袁轶群 , 周玲 , 邓卫平 , 陈思佳 , 胡海清 , 鹿秀海 , 胡永奇 , 李志兰 , 戴芸 , 胡妮娅 , 曾令兵 , 钱敏建 , 黄晓春 , 潘芬 , 蒋娜 , 胡娟 , 朱召芹 , 金英 , 杨乐园 , 刘淮玉 , 李妮娅 , 翁丽贞 , 夏益兰 , 李娜 , 高晶 , 张晓雪 , 刘云 , 陈旭 , 戴俊华 , 刘军 , 钱朵朵 , 侯伟伟 , 王月玲 , 孙静芳 , 黄莉莉 , 舒文 , 李丽 , 时建英 , 张灏旻 , 刘春红 , 杨卫华 , 王芳 , 吴文娟 . 2025年中国华东地区真菌耐药监测报告[J]. 诊断学理论与实践, 2026 , 25(03) : 287 -307 . DOI: 10.16150/j.1671-2870.2026.03.005
Objective This study aims to monitor the antifungal susceptibility of clinically isolated fungi in East China in 2025, thereby providing a reference for clinical diagnosis and treatment. Methods A retrospective analysis was conducted on clinical fungi collected by the East China Invasive Fungal Infection Group (ECIFIG) from January to December 2025. Species identification was performed using morphological characteristics combined with mass spectrometry, and the results were verified by internal transcribed spacer (ITS) sequencing and β-tubulin gene sequencing. Antifungal susceptibility testing for azoles (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole), echinocandins (micafungin, anidulafungin, caspofungin), amphotericin B, and flucytosine was carried out using the broth microdilution method. Results In 2025, a total of 2 044 yeast isolates were collected in East China, and blood was the primary specimen type, accounting for 37.06% (763/2 044). The yeast species distribution was as follows: Candida albicans 38.51% (793/2 044), Candida tropicalis 18.89% (389/2 044), Candida parapsilosis 16.61% (342/2 044), Candida glabrata 15.20% (313/2 044), and Candida krusei 1.75% (36/2 044). A total of 310 filamentous fungal isolates were collected in East China, predominantly Aspergillus species: Aspergillus fumigatus (62.26%), Aspergillus flavus (26.45%), Aspergillus niger (5.81%), and Aspergillus terreus (3.55%). Filamentous fungi were mainly isolated from respiratory specimens, with sputum specimen accounting for 53.23% and bronchoalveolar lavage fluid (BALF) specimen accounting for 31.29%. Resistance in Candida species was primarily observed for azoles. The fluconazole resistance rate in C. albicans was 3.66%, and the rate of non-wild-type (NWT) isolates for posaconazole was 6.81%. For C. tropicalis, the fluconazole resistance rate was 29.05%, the voriconazole non-susceptible rate was 24.45%, the itraconazole NWT rate was 17.48%, and the posaconazole NWT rate was 61.18%. C. parapsilosis showed a fluconazole resistance rate of 11.7% and an amphotericin B NWT rate of 2.30%. C. glabrata exhibited a fluconazole resistance rate of 5.75%, and the NWT rates for itraconazole, posaconazole, and voriconazole were 1.92%, 12.78%, and 28.12%, respectively. For A. fumigatus, the voriconazole intermediate rate was 3.63%, and the resistance rate was 5.18%. The isavuconazole intermediate rate was 1.04%, the resistance rate was 4.70%, and the NWT rate for itraconazole was 3.11%. All A. flavus isolates were wild-type for caspofungin, amphotericin B, and azoles. Conclusions In 2025, East China Fungal Surveillance Network collects 2 044 yeast isolates, primarily from blood specimens, with C. albicans being the most prevalent. A total of 310 filamentous fungal isolates are collected, mainly from respiratory specimens, with A. fumigatus being the most common. Azole resistance in C. tropicalis is significantly higher than that in other Candida species. The azole resistance rate in A. fumigatus is 5.18%, showing an increase compared to it in previous years. No azole-resistant A. flavus isolates have been detected.
| [1] | KAINZ K, BAUER M A, MADEO F, et al. Fungal infections in humans: The silent crisis[J]. Microb Cell, 2020, 7(6):143-145. |
| [2] | CORNELY O A, SPRUTE R, BASSETTI M, et al. Global guideline for the diagnosis and management of candidiasis: An initiative of the ECMM in cooperation with ISHAM and ASM[J]. Lancet Infect Dis, 2025, 25(5):e280-e293. |
| [3] | World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action[M]. Geneva: World Health Organization, 2022. |
| [4] | KULLBERG B J, ARENDRUP M C. Invasive candidiasis[J]. N Engl J Med, 2015, 373(15):1445-1456. |
| [5] | CADENA J, THOMPSON G R, PATTERSON T F. Aspergillosis: Epidemiology, diagnosis, and treatment[J]. Infect Dis Clin North Am, 2021, 35(2):415-434. |
| [6] | ZHANG W, ZHANG H, ZHAN M, et al. Epidemiological characteristics of invasive Aspergillus isolates: Morpho-logy, drug susceptibility, and mutations in azole drug targets[J]. J Infect Public Health, 2025, 18(1):102612. |
| [7] | VAN DE VEERDONK F L, CARVALHO A, WAUTERS J, et al. Aspergillus fumigatus biology, immunopathogenicity and drug resistance[J]. Nat Rev Microbiol, 2025, 23(10):652-666. |
| [8] | DONNELLY J P, CHEN S C, KAUFFMAN C A, et al. Revision and update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium[J]. Clin Infect Dis, 2020, 71(6):1367-1376. |
| [9] | 尚红, 王毓三, 申子瑜. 全国临床检验操作规程[S]. 4版. 北京: 人民卫生出版社, 2015,781-790. |
| SHANG H, WANG Y S, SHEN Z Y. National clinical laboratory operating procedures[S]. 4 ed. Beijing: The People's Health Press, 2015,781-790. | |
| [10] | CLSI. Epidemiological cutoff values for antifungal susceptibility testing[S]. 4th ed. Clinical and Laboratory Standards Institute:CLSI supplement M57S, 2022. |
| [11] | CLSI. Performance standards for antjfungal susceptibility testing of yeasts[S]. 4th ed. Clinical and Laboratory Standards Institute:CLSI supplement M27M44S, 2026. |
| [12] | Clinical Laboratory Standards Institute (CLSL). Performance standards for antifungal susceptibility testing of Filamentous fungi[S]. 3th Ed, M38M51S, 2022. |
| [13] | LI Y, GU C, YANG Y, et al. Epidemiology, antifungal susceptibility, risk factors, and mortality of persistent candidemia in adult patients in China: A 6-year multicenter retrospective study[J]. BMC Infect Dis, 2023, 23(1):369. |
| [14] | VáZQUEZ-OLVERA R, VOLKOW P, VELáZQUEZ-ACOSTA C, et al. Candida bloodstream infection in patients with cancer: A retrospective analysis of an 11-year period[J]. Rev Iberoam De Micología, 2023, 40(1):3-9. |
| [15] | XIAO M, CHEN S C, KONG F, et al. Distribution and antifungal susceptibility of Candida Species causing candidemia in China: An update from the CHIF-NET study[J]. J Infect Dis, 2020, 221(Supplement_2):S139-S147. |
| [16] | SIOPI M, TARPATZI A, KALOGEROPOULOU E, et al. Epidemiological trends of fungemia in Greece with a focus on candidemia during the recent financial crisis: A 10-year survey in a tertiary care academic hospital and review of literature[J]. Antimicrob Agents Chemother, 2020, 64(3):e01516-e01519. |
| [17] | PAPPAS P G, KAUFFMAN C A, ANDES D R, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America[J]. Clin Infect Dis, 2016, 62(4):e1-e50. |
| [18] | 王利可, 陈小娟, 张优, 等. 海南省2013—2022年某真菌监测网点分离念珠菌的耐药性及血清学检测[J]. 中国热带医学, 2024, 24(2):136-142. |
| WANG L K, CHEN X J, ZHANG Y, et al. Drug resistance and serological detection of Candida isolated from a fungal surveillance network in Hainan province from 2013 to 2022[J]. Chin Trop Med, 2024, 24(2):136-142. | |
| [19] | 李彦, 邓劲, 康梅. 四川地区29家医院临床分离真菌的菌种分布及耐药性监测[J]. 中国抗生素杂志, 2023, 48(12):1403-1408. |
| LI Y, DENG J, KANG M. Distribution and drug resistance monitoring of clinical fungi isolated from 29 hospitals in Sichuan area[J]. Chin J Antibiot, 2023, 48(12):1403-1408. | |
| [20] | XIAO Z, WANG Q, ZHU F, et al. Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: A retrospective study from 2011 to 2017 in a teaching hospital in China[J]. Antimicrob Resist Infect Control, 2019, 8(1):89. |
| [21] | LASS-FL?RL C, KANJ S S, GOVENDER N P, et al. Invasive candidiasis[J]. Nat Rev Dis Primers, 2024,10:20. |
| [22] | 中华医学会呼吸病学分会. 侵袭性肺真菌病诊断与治疗指南(2025年版)[J]. 中华结核和呼吸杂志, 2025, 48(12):1104-1126. |
| Chinese Thoracic Society. Clinical practice guidelines for the diagnosis and management of invasive pulmonary fungal diseases (2025 Edition)[J]. Chin J Tuberic Respir Dis, 2025, 48(12):1104-1126. | |
| [23] | LIN H, GUO J, LI Y, et al. In vitro antifungal susceptibi-lity profile and genotypic characterization of clinical Aspergillus isolates in Eastern China on behalf of Eastern China Invasive Fungi Infection Group[J]. Med Mycol, 2023, 61(9):myad082. |
| [24] | 慎慧, 郭建, 张旻, 等. 上海地区临床分离念珠菌的耐药性监测[J]. 中国感染与化疗杂志, 2019, 19(3):292-299. |
| SHEN H, GUO J, ZHANG M, et al. Surveillance of drug resistance of clinical Candida isolates in Shanghai[J]. Chin J Infect Chemother, 2019, 19(3):292-299. | |
| [25] | 王东江, 吴文娟, 郭建, 等. 2018-2022年华东地区临床分离念珠菌耐药性监测[J]. 中国感染与化疗杂志, 2024, 24(4):402-409. |
| WANG D J, WU W J, GUO J, et al. Surveillance of antifungal resistance in clinical isolates of Candida spp.in East China Invasive Fungal Infection Group from 2018 to 2022[J]. Chin J Infect Chemother, 2024, 24(4):402-409. | |
| [26] | WANG Y, FAN X, WANG H, et al. Continual decline in azole susceptibility rates in Candida tropicalis over a 9-year period in China[J]. Front Microbiol, 2021,12:702839. |
| [27] | CEBALLOS-GARZON A, PE?UELA A, VALDERRAMA-BELTRáN S, et al. Emergence and circulation of azole-resistant C. albicans, C. Auris and C. parapsilosis bloodstream isolates carrying Y132F, K143R or T220L Erg11p substitutions in Colombia[J]. Front Cell Infect Microbiol, 2023,13:1136217. |
| [28] | 陈维琳, 侯杰, 彭亮, 等. 四川地区血源性热带念珠菌分子流行病学研究及氟康唑耐药机制初探[J]. 四川大学学报(医学版), 2025, 56(5):1380-1386. |
| CHEN W L, HOU J, PENG L, et al. Molecular epidemio-logy and fluconazole resistance mechanisms in Candida tropicalis isolates from bloodstream infections in Sichuan,China[J]. J Sichun Uni (Med Sci), 2025, 56(5):1380-1386. | |
| [29] | GOVRINS M, LASS-FL?RL C. Candida parapsilosis complex in the clinical setting[J]. Nat Rev Microbiol, 2024, 22(1):46-59. |
| [30] | 林慧萍, 郭建. 黄曲霉复合群临床菌株抗真菌药物敏感性特征[J]. 中华检验医学杂志, 2026, 49(1):78-83. |
| LIN H P, GUO J. Distribution and antifungal susceptibi-lity characteristics of clinically isolated Aspergillus flavus complex[J]. Chin J Lab Med, 2026, 49(1):78-83. |
/
| 〈 |
|
〉 |